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Caffeine inhibits TGFβ
activation in epithelial cells,
interrupts ﬁbroblast responses
to TGFβ, and reduces
established ﬁbrosis in ex vivo
precision-cut lung slices
Abstract
Caffeine is a commonly used food additive
found naturally in many products. In addition
to potently stimulating the central nervous
system caffeine is able to affect various
systems within the body including the
cardiovascular and respiratory systems.
Importantly, caffeine is used clinically to treat
apnoea and bronchopulmonary dysplasia in
premature babies. Recently, caffeine has been
shown to exhibit antiﬁbrotic effects in the liver
in part through reducing collagen expression
and deposition, and reducing expression of
the proﬁbrotic cytokine TGFβ. The potential
antiﬁbrotic effects of caffeine in the lung have
not previously been investigated. Using a
combined in vitro and ex vivo approach we
have demonstrated that caffeine can act as an
antiﬁbrotic agent in the lung by acting on two
distinct cell types, namely epithelial cells and
ﬁbroblasts. Caffeine inhibited TGFβ activation
by lung epithelial cells in a concentration-
dependent manner but had no effect on TGFβ
activation in ﬁbroblasts. Importantly, however,
caffeine abrogated proﬁbrotic responses to
TGFβ in lung ﬁbroblasts. It inhibited basal
expression of the α-smooth muscle actin gene
and reduced TGFβ-induced increases in
proﬁbrotic genes. Finally, caffeine reduced
established bleomycin-induced ﬁbrosis after
5 days treatment in an ex vivo precision-cut
lung slice model. Together, these ﬁndings
suggest that there is merit in further
investigating the potential use of caffeine, or
its analogues, as antiﬁbrotic agents in the
lung.
Caffeine (1,3,7-tri-methylxanthine) is one
of the most commonly consumed food
additives worldwide and has wide-ranging
pharmacological activities including
effects on the central nervous, cardiovas-
cular and respiratory systems. It can act as
an antagonist of adenosine receptors, an
inhibitor of phosphodiesterases and an
activator of ryanodine receptors. Caffeine
is similar in structure and function to
theophylline and can improve lung func-
tion in asthmatics by inducing broncho-
dilation.1 Furthermore, caffeine citrate
(Calﬁcit) is clinically approved and com-
monly used to treat bronchopulmonary
dysplasia and apnoea in premature
infants.2 In recent years, caffeine has been
shown to exhibit antiﬁbrotic effects in the
liver. Consumption of caffeine, often in
the form of coffee, is associated with
reduced hepatic ﬁbrosis in patients suffer-
ing from chronic hepatitis C virus infec-
tion.3 In in vivo animal models of liver
ﬁbrosis caffeine can reduce collagen
deposition and collagen mRNA,4 5 and
can block expression of the proﬁbrotic
cytokine TGFβ.6 Furthermore, caffeine
can inhibit proﬁbrotic responses in
hepatic stellate cells, the key effector cell
in the development of liver ﬁbrosis.7
Despite the known effects of caffeine on
lung function the potential antiﬁbrotic
effects of caffeine in the lung have not
previously been investigated.
Figure 1 (A) Immortalised human bronchial epithelial cells (iHBECs) were stimulated with increasing concentrations of caffeine for 4 hours and
PSmad2 levels measured. Figure shows mean data±SEM from three independent experiments. (B) iHBECs were stimulated with 50 mM caffeine and
PAI1 mRNA levels measured. Data are expressed as mean fold change over control (0 h)±SEM from three independent experiments. (C) Non-ﬁbrotic
control (NL) and idiopathic pulmonary ﬁbrosis (IPF) ﬁbroblasts were stimulated with increasing concentrations of caffeine and TGFβ activation
assessed by TMLC reporter assay. Figure shows mean data±SEM from n=3 NL and n=3 IPF donors. (D) NL and IPF ﬁbroblasts were stimulated with
50 mM caffeine and ACTA2 mRNA levels measured. Data are expressed as mean fold change over control (0 h for NL or IPF, respectively)±SEM.
Figure shows mean data from n=3 NL and n=3 IPF donors. *p<0.05 **p<0.01.
Thorax June 2016 Vol 71 No 6 565
Research letter
 o
n
 19 Novem
ber 2018 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2015-208215 on 24 February 2016. Downloaded from 
In the present study we have used a
combination of in vitro cell and ex vivo
tissue approaches to investigate the
hypothesis that caffeine can inhibit ﬁbro-
genesis in the lung. The pathogenesis of
pulmonary ﬁbrosis is thought to involve
activation of TGFβ by lung epithelial cells
following repeated microinjury to the epi-
thelium, causing transdifferentiation of
ﬁbroblasts into proﬁbrotic myoﬁbroblasts,
which ultimately leads to deposition of
extracellular matrix within the lung inter-
stitium and deteriorating lung function
and/or death. We have demonstrated that
caffeine inhibits endogenous TGFβ activa-
tion in immortalised human bronchial epi-
thelial cells in a concentration-dependent
manner by measuring levels of phos-
phorylated Smad2 (P-Smad2) (ﬁgure 1A).
Furthermore, basal levels of the
TGFβ-induced gene PAI1 were inhibited
by caffeine over 24 h (ﬁgure 1B).
Importantly, the effect of caffeine on
TGFβ activation was speciﬁc to epithelial
cells since caffeine had no effect on
endogenous TGFβ activation in lung
ﬁbroblasts isolated from either non-
ﬁbrotic control (NL) donors or patients
with idiopathic pulmonary ﬁbrosis (IPF)
(ﬁgure 1C). Caffeine did not affect cell
viability in any cell type tested (see online
supplementary ﬁgures S1B–D).
Increased expression of α-smooth
muscle actin (α-SMA) in ﬁbroblasts is a
key marker of ﬁbroblast-myoﬁbroblast
transdifferentiation. We therefore assessed
the effect of caffeine on expression of
α-SMA (ACTA2) transcript in NL and IPF
ﬁbroblasts as a surrogate for measuring
ﬁbroblast-myoﬁbroblast transdifferentia-
tion. Caffeine inhibited basal ACTA2
mRNA expression in both diseased and
control ﬁbroblasts (ﬁgure 1D) suggesting
that it can interrupt ﬁbroblast-
myoﬁbroblast transdifferentiation, a key
ﬁbrogenic process.
To further investigate the effect of caf-
feine on proﬁbrotic responses in lung
ﬁbroblasts we investigated caffeine’s
actions on TGFβ-induced gene expres-
sion. TGFβ increased expression of PAI1,
ACTA2 and TGFB1 in IPF ﬁbroblasts after
24 h and caffeine abrogated these
responses (ﬁgure 2A–C). This effect was
also observed in NL ﬁbroblasts (see online
supplementary ﬁgures E–G). Together
these in vitro data demonstrate that caf-
feine may inhibit ﬁbrogenesis through
concomitant, but distinct, actions on both
epithelial cells and lung ﬁbroblasts. It has
previously been suggested that inhibition
of PDE4 can mediate TGFβ-induced
ﬁbroblast to myoﬁbroblast differentiation,
therefore we hypothesised that caffeine’s
actions on TGFβ-induced ﬁbroblast
responses might be mediated via PDE4.8
To investigate this further we used the
PDE4 inhibitor roﬂumilast. Treatment of
IPF ﬁbroblasts with 10 mM roﬂumilast did
Figure 2 Idiopathic pulmonary ﬁbrosis (IPF) ﬁbroblasts were pretreated with 0 μM or 50 μM caffeine for 30 min then stimulated with 0 ng/mL or
2 ng/mL TGFβ for 24 h and (A) PAI1; (B) ACTA2; (C) TGFB1 gene expression measured. Data are expressed as mean fold change over control (0 h,
0 ng/mL TGFβ)±SEM from experiments performed on cells from three individual donors. IPF ﬁbroblasts were pretreated with 0 μM or 10 μM
roﬂumilast for 30 min then stimulated with 0 ng/mL or 2 ng/mL TGFβ for 24 h and (D) PAI1; (E) ACTA2; (F) TGFB1 gene expression measured. Data
are expressed as mean fold change over control (0 h, 0 ng/mL TGFβ)±SEM from experiments performed on cells from four individual donors. (G)
Precision-cut lung slices (PCLS) were prepared from the lungs of saline-treated and bleomycin-treated mice and collagen levels measured after 5 days
in ex vivo culture. Data are expressed as mean collagen (mg) per mg of lung tissue±SEM from n=16 PCLS/group. (H) PCLS were prepared from the
lungs of bleomycin-treated or saline-treated mice and treated for 5 days ex vivo with 0 μM, 25 μM, 50 μM and 100 μM caffeine. Data are expressed
as mean collagen (mg) per mg of lung tissue±SEM from n=6 bleomycin PCLS or n=2 saline PCLS. *p<0.05, **p<0.01, ****p<0.0001.
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not recapitulate the effects of caffeine on
TGFβ-induced PAI1, ACTA2 and TGFB1
mRNA expression (ﬁgure 2D–F). These
data suggest the inhibitory effect of caf-
feine on TGFβ-induced gene expression is
independent of its effects on PDE4.
Finally, to conﬁrm that caffeine can act
as an antiﬁbrotic agent in the lung, we
have used a novel ex vivo precision-cut
lung slice (PCLS) model of pulmonary
ﬁbrosis. PCLS were prepared from mice
treated with either bleomycin or saline
control for 28 days and the presence of
ﬁbrosis determined using high-
performance liquid chromatography.
PCLS from bleomycin-treated animals
contained signiﬁcantly higher levels of
collagen than PCLS from saline-treated
animals (ﬁgure 2D). Crucially, caffeine
was also able to signiﬁcantly reduce colla-
gen deposition in a concentration-
dependent manner over 5 days within
bleomycin-PCLS (ﬁgure 2E).
These data demonstrate for the ﬁrst
time that caffeine can act as an antiﬁbrotic
agent in the lung. Concentrations of caf-
feine achieved physiologically are gener-
ally less than 70 mM caffeine,9
furthermore, previous in vivo animal
studies have shown antiﬁbrotic effects in
the liver with serum concentrations
ranging from 38 mM to 59 mM.4 Our
studies showed antiﬁbrotic effects at con-
centrations between 50 mM and 100 mM
supporting the hypothesis that physio-
logical concentrations of caffeine may
have antiﬁbrotic effects in the lung. In the
lung, caffeine appears to exhibit its antiﬁ-
brotic effects through distinct actions on
both epithelial cells and ﬁbroblasts, which
are two of the key effector cells involved
in the pathogenesis of pulmonary ﬁbrosis.
It has previously been reported that caf-
feine is capable of interrupting
TGFβ-induced Smad signalling in a lung
epithelial cancer cell line.10 However,
these data demonstrate that caffeine can
also inhibit endogenous TGFβ activation
by lung epithelial cells, which is the ﬁrst
report showing that caffeine can inhibit
endogenous TGFβ activation in any cell
type. Additionally, caffeine can interrupt
ﬁbroblastic proﬁbrotic responses to TGFβ
and these data show that caffeine inhibits
TGFβ-induced increases in proﬁbrotic
genes including PAI1, ACTA2 and TGFB1.
This ﬁnding supports existing data from
the liver showing that caffeine can inter-
rupt proﬁbrotic responses, particularly
collagen and TGFβ expression in mesen-
chymal cells.4–6 Taken together, the data
described highlight a potentially import-
ant role for caffeine and its analogues in
the treatment of ﬁbrotic lung disease.
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